
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings is the market leader in orthopedic reconstructive implants and surgical equipment, with a dominant share of the US, Europe, and Japan markets. The recent acquisitions of Centerpulse and Biomet have strengthened the company's position in the market. Despite a more complicated first quarter, the company beat expectations on sales, margins, and EPS. While there are some short-term challenges, such as the CFO's departure, factors such as strong product innovation and a direct sales model transformation suggest long-term growth potential for the company. As a result, I have a positive outlook on Zimmer Biomet Holdings' stock.
Bears say
Zimmer Biomet Holdings is facing a number of challenges that are impacting its outlook for the future. Investments in Paragon 28 and Monogram are expected to continue, but with a pause on mergers and acquisitions and potential slowdown in sales due to the continued impact of the pandemic, the company's growth potential is limited. The recent spin-off of its dental and spine businesses also indicates a potential shift in focus and strategy, which could affect overall performance. The company's financials show mixed results, with a projected 2% revenue growth in 2026 and 2027, and a slight decline in EPS from $9.11 prior to $9.71 in 2028.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares